申请人:Zeneca Limited
公开号:US05866611A1
公开(公告)日:1999-02-02
Compounds of formula I, and their pharmaceutically acceptable salts, ##STR1## in which R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl or alkenyl; or NR.sup.1 R.sup.2 is a heterocyclic group; A is trimethylene optionally substituted by alkyl and the phenyl ring is optionally substituted by substituents such as halogeno, alkenyl, amino, cyano, ureido, alkyl, carbamoylalkyl, alkanoylamino, alkoxycarbonyl, N-alkyl-alkanoylamino, alkanoyl and amines thereof; are inhibitors of squalene synthese and hence useful in treating diseases in which a lowering of cholesterol is desirable. As well as the use of these compounds in medicine, novel compounds, processes for their preparation and pharmaceutical compositions are also referred to.
式I的化合物及其药学上可接受的盐,其中R.sup.1和R.sup.2分别为氢、烷基、环烷基、环烷基烷基、苯基烷基或烯基;或NR.sup.1 R.sup.2是杂环基团;A是可选择地由烷基取代的三亚甲基,苯环可选择地由卤素、烯基、氨基、氰基、脲基、烷基、碳酰胺基烷基、烷酰氨基、烷氧羰基、N-烷基-烷酰氨基、烷酰基及其胺基取代基取代;这些化合物是角鲨烯合成酶的抑制剂,因此在治疗降低胆固醇的疾病中有用。除了这些化合物在医学上的用途外,还提到了新颖的化合物、其制备方法和药物组合物。